MY185551A - Antibody formulations - Google Patents

Antibody formulations

Info

Publication number
MY185551A
MY185551A MYPI2015002310A MYPI2015002310A MY185551A MY 185551 A MY185551 A MY 185551A MY PI2015002310 A MYPI2015002310 A MY PI2015002310A MY PI2015002310 A MYPI2015002310 A MY PI2015002310A MY 185551 A MY185551 A MY 185551A
Authority
MY
Malaysia
Prior art keywords
formulations
antibody formulations
methods
trehalose
biotechnology
Prior art date
Application number
MYPI2015002310A
Other languages
English (en)
Inventor
Yatin Gokarn
Isidro E Zarraga
Jonathan Zarzar
Thomas Pataoff
Christine Wurth
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51625441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY185551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MY185551A publication Critical patent/MY185551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
MYPI2015002310A 2013-03-13 2014-03-13 Antibody formulations MY185551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780899P 2013-03-13 2013-03-13
PCT/US2014/026824 WO2014160490A1 (en) 2013-03-13 2014-03-13 Antibody formulations

Publications (1)

Publication Number Publication Date
MY185551A true MY185551A (en) 2021-05-19

Family

ID=51625441

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2015002310A MY185551A (en) 2013-03-13 2014-03-13 Antibody formulations
MYPI2019002171A MY189047A (en) 2013-03-13 2014-03-13 Antibody formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2019002171A MY189047A (en) 2013-03-13 2014-03-13 Antibody formulations

Country Status (17)

Country Link
US (3) US10010611B2 (enExample)
EP (2) EP2968553B1 (enExample)
JP (2) JP6511609B2 (enExample)
KR (2) KR102048512B1 (enExample)
CN (2) CN110538322A (enExample)
AR (1) AR095396A1 (enExample)
AU (2) AU2014243783B2 (enExample)
BR (1) BR112015022210A8 (enExample)
CA (1) CA2906057A1 (enExample)
IL (2) IL240886B (enExample)
MX (2) MX365567B (enExample)
MY (2) MY185551A (enExample)
NZ (2) NZ711567A (enExample)
RU (2) RU2694055C2 (enExample)
SG (2) SG10201913932VA (enExample)
WO (1) WO2014160490A1 (enExample)
ZA (2) ZA201506981B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968553B1 (en) 2013-03-13 2020-08-12 F.Hoffmann-La Roche Ag Antibody formulations
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
BR112017014376A2 (en) * 2015-01-28 2018-05-02 Pfizer Inc. stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
MA45450B1 (fr) 2016-06-27 2021-04-30 Morphosys Ag Formulations d'anticorps anti-cd19
CN107384932B (zh) 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
US11865175B1 (en) 2017-04-28 2024-01-09 Cedars-Sinai Medical Center Post-transplantation prophylaxis and treatments for antibody-mediated rejection of solid organ transplant
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
CN107899020A (zh) * 2017-08-11 2018-04-13 百奥泰生物科技(广州)有限公司 Cd20阳性疾病治疗的化合物及方法
US20190099489A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. Novel Formulations Which Stabilize Low Dose Antibody Compositions
US20200390693A1 (en) * 2017-12-22 2020-12-17 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
WO2021068971A1 (en) * 2019-10-12 2021-04-15 Bio-Thera Solutions, Ltd. Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases
CN115066262B (zh) * 2020-03-04 2025-07-15 上海复宏汉霖生物技术股份有限公司 一种包含贝伐珠单抗的药物配制剂
WO2022265591A1 (en) * 2021-06-18 2022-12-22 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bevacizumab

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3228284C2 (de) 1982-07-29 1986-11-27 Messerschmitt-Bölkow-Blohm GmbH, 8000 München Niederhaltevorrichtung für entfaltbare Funktionselemente
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP2095873A1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2447114A1 (en) 2001-05-16 2002-11-21 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
EA014802B1 (ru) 2001-08-23 2011-02-28 Генмаб А/С АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
JP2007525410A (ja) 2003-01-17 2007-09-06 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法
EP1587921B1 (en) 2003-01-22 2010-07-28 GlycArt Biotechnology AG Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DE10314595B4 (de) 2003-03-31 2006-05-04 Infineon Technologies Ag Verfahren zur Herstellung von Transistoren unterschiedlichen Leitungstyps und unterschiedlicher Packungsdichte in einem Halbleitersubstrat
WO2005023177A2 (en) 2003-05-21 2005-03-17 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
HRP20100303T1 (hr) 2003-11-05 2010-07-31 Roche Glycart Ag Cd20 antitijela s povećanim afinitetom vezivanja fc receptora i efektorskim djelovanjem
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5373396B2 (ja) 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US20090110688A1 (en) 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
PL2234600T3 (pl) * 2007-12-21 2015-02-27 Hoffmann La Roche Preparat przeciwciała
CN101965183A (zh) * 2008-02-21 2011-02-02 伊斯塔药品公司 作为佐剂的眼用nsaid
ES2658596T3 (es) 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
WO2010083162A2 (en) * 2009-01-13 2010-07-22 The Board Of Regents Of The University Of Texas System Unc-45a splice variants based cancer diagnostics and therapeutics
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102770158B (zh) * 2009-12-21 2016-10-19 霍夫曼-拉罗奇有限公司 抗体配制剂
WO2011109789A2 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
GB201107170D0 (en) * 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
EP3578203A1 (en) 2011-10-28 2019-12-11 Integritybio Inc. Protein formulations containing amino acids
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
EP2968553B1 (en) 2013-03-13 2020-08-12 F.Hoffmann-La Roche Ag Antibody formulations
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
CA3026668C (en) 2018-08-22 2020-06-30 Gulfstream Inc. Bubble generation system

Also Published As

Publication number Publication date
WO2014160490A8 (en) 2015-07-30
AU2019201566A1 (en) 2019-03-28
MX365567B (es) 2019-06-07
IL275103A (en) 2020-07-30
JP6511609B2 (ja) 2019-05-22
AU2019201566B2 (en) 2020-12-10
JP2016515124A (ja) 2016-05-26
RU2694055C2 (ru) 2019-07-09
RU2015143607A3 (enExample) 2018-03-20
CA2906057A1 (en) 2014-10-02
SG10201913932VA (en) 2020-03-30
NZ751452A (en) 2020-04-24
NZ711567A (en) 2020-04-24
EP3744345B1 (en) 2022-02-09
JP2019055962A (ja) 2019-04-11
KR20150130395A (ko) 2015-11-23
KR102048512B1 (ko) 2019-11-26
CN105209069B (zh) 2019-08-23
HK1212614A1 (zh) 2016-06-17
ZA202005525B (en) 2022-04-28
KR20190131623A (ko) 2019-11-26
IL240886B (en) 2020-09-30
EP2968553B1 (en) 2020-08-12
RU2015143607A (ru) 2017-04-20
ZA201506981B (en) 2021-03-31
AU2014243783B2 (en) 2018-12-13
US10925966B2 (en) 2021-02-23
RU2019120404A (ru) 2019-08-06
BR112015022210A2 (pt) 2017-10-10
MY189047A (en) 2022-01-21
KR102127085B1 (ko) 2020-06-26
AR095396A1 (es) 2015-10-14
JP6814962B2 (ja) 2021-01-20
EP3744345A1 (en) 2020-12-02
MX2015011425A (es) 2016-04-20
US20140314748A1 (en) 2014-10-23
EP2968553A4 (en) 2016-10-19
BR112015022210A8 (pt) 2018-01-23
MX2019006633A (es) 2021-12-08
IL240886A0 (en) 2015-10-29
US20200179516A1 (en) 2020-06-11
EP2968553A1 (en) 2016-01-20
US20180280514A1 (en) 2018-10-04
CN105209069A (zh) 2015-12-30
SG11201507475UA (en) 2015-10-29
WO2014160490A1 (en) 2014-10-02
CN110538322A (zh) 2019-12-06
AU2014243783A1 (en) 2015-10-01
US10010611B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
MX2019006633A (es) Formulaciones de anticuerpo.
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
PH12019501931A1 (en) Anti-pdl1 antibody formulations
MY159156A (en) Antibody formulation
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
MX2017003121A (es) Formulaciones de anticuerpos.
MY196882A (en) Recombinant binding proteins and their use
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
PH12018502361B1 (en) Gdf15 fusion proteins and uses thereof
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
MX2024005945A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX377080B (es) Construcciones de variantes de sirp-alfa y sus usos.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения